1. Home
  2. BCS vs REGN Comparison

BCS vs REGN Comparison

Compare BCS & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barclays PLC

BCS

Barclays PLC

HOLD

Current Price

$23.41

Market Cap

68.4B

Sector

Finance

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$722.54

Market Cap

59.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCS
REGN
Founded
1690
1988
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.4B
59.5B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
BCS
REGN
Price
$23.41
$722.54
Analyst Decision
Hold
Buy
Analyst Count
1
23
Target Price
N/A
$793.74
AVG Volume (30 Days)
5.6M
1.1M
Earning Date
10-22-2025
10-28-2025
Dividend Yield
1.86%
0.49%
EPS Growth
45.84
2.88
EPS
0.54
41.59
Revenue
$34,970,562,135.00
$14,247,800,000.00
Revenue This Year
$20.45
$1.95
Revenue Next Year
$5.12
$5.47
P/E Ratio
$10.13
$17.38
Revenue Growth
10.24
2.89
52 Week Low
$12.14
$476.49
52 Week High
$23.57
$800.99

Technical Indicators

Market Signals
Indicator
BCS
REGN
Relative Strength Index (RSI) 70.41 56.05
Support Level $22.95 $720.07
Resistance Level $22.91 $790.98
Average True Range (ATR) 0.33 21.86
MACD 0.18 -5.25
Stochastic Oscillator 94.32 34.89

Price Performance

Historical Comparison
BCS
REGN

About BCS Barclays PLC

Barclays is a universal bank headquartered in the United Kingdom. It operates via five principal segments; UK (retail), UK corporate bank, private bank and wealth management, investment bank, and US consumer bank. In its UK segment, the bank provides current accounts, mortgages, savings and investment management services, credit cards, and business banking services to retail clients and small and medium-size enterprises. The international segment includes a corporate bank offering banking solutions to large corporates, a bulge-bracket global investment bank, and a credit card and payments business.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: